A detailed history of Lion Point Capital, LP transactions in Milestone Pharmaceuticals Inc. stock. As of the latest transaction made, Lion Point Capital, LP holds 2,340,207 shares of MIST stock, worth $4.19 Million. This represents 6.61% of its overall portfolio holdings.

Number of Shares
2,340,207
Previous 2,300,207 1.74%
Holding current value
$4.19 Million
Previous $4.12 Million 24.97%
% of portfolio
6.61%
Previous 2.63%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

BUY
$1.29 - $1.83 $51,600 - $73,200
40,000 Added 1.74%
2,340,207 $3.09 Million
Q1 2024

May 15, 2024

BUY
$1.4 - $2.2 $910,000 - $1.43 Million
650,000 Added 39.39%
2,300,207 $4.12 Million
Q4 2023

Feb 14, 2024

BUY
$1.67 - $3.39 $2 Million - $4.07 Million
1,200,000 Added 266.54%
1,650,207 $2.76 Million
Q2 2023

Aug 14, 2023

BUY
$2.85 - $4.4 $71,250 - $110,000
25,000 Added 5.88%
450,207 $1.28 Million
Q4 2022

Feb 14, 2023

SELL
$3.53 - $9.5 $4 Million - $10.8 Million
-1,132,026 Reduced 72.69%
425,207 $1.68 Million
Q3 2022

Nov 14, 2022

BUY
$5.86 - $9.43 $3.57 Million - $5.74 Million
608,663 Added 64.17%
1,557,233 $11.2 Million
Q2 2022

Aug 15, 2022

BUY
$5.13 - $7.37 $1.36 Million - $1.95 Million
265,000 Added 38.77%
948,570 $5.63 Million
Q1 2022

May 16, 2022

BUY
$4.1 - $8.24 $2.8 Million - $5.63 Million
683,570 New
683,570 $4.39 Million

Others Institutions Holding MIST

About Milestone Pharmaceuticals Inc.


  • Ticker MIST
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 30,010,900
  • Market Cap $53.7M
  • Description
  • Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company is developing etripamil, a novel channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II cl...
More about MIST
Track This Portfolio

Track Lion Point Capital, LP Portfolio

Follow Lion Point Capital, LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Lion Point Capital, LP, based on Form 13F filings with the SEC.

News

Stay updated on Lion Point Capital, LP with notifications on news.